Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linezolid in the Treatment of Subjects With Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus.

Trial Profile

Linezolid in the Treatment of Subjects With Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linezolid (Primary) ; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
  • Focus Therapeutic Use
  • Acronyms ZEPHYR
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jun 2017 Results characterizing resistance patterns in baseline methicillin-resistant Staphylococcus aureus (MRSA) isolates (n=427) presented at the ASM Microbe 2017
    • 18 May 2013 Results of the piggybacked economic analysis in the USA presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 27 Apr 2013 Results of a post-hoc economic analysis in Spain presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top